Characterization and human osteoblastic proliferation- and differentiation-stimulatory effects of phosphatidylcholine liposomes-encapsulated propranolol hydrochloride
Affiliations: Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan | Department of Orthopaedics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan | Department of Food Science and Nutrition, Meiho University, Pingtung, Taiwan | Department of Beauty Science, Meiho University, Pingtung, Taiwan | Graduate Institute of Applied Health and Biotechnology, Meiho University, Pingtung, Taiwan
Note: [] These authors contributed equally to this work.
Note: [] Address for correspondence: Dr. Han Hsiang Huang, 23 Pingkung Road, Neipu Hsiang, Pingtung 91202, Taiwan. E-mail: hhuang.adsl@msa.hinet.net
Abstract: DMPC and DSPC liposomes were prepared via thin film hydration method followed by sonication. Propranolol solution was incorporated into liposomes at hydration stage. TEM images showed the sizes of DSPC and DMPC were around 88 and 137 nm, respectively. The highest encapsulation ratio of propranolol was approximately 70% using DSPC/CHO/OCT liposomes, which release the drug over 60% in 24 h and reached 100% in 48 h. Both propranolol (10−8–10−6 M) and DSCP liposomes-encapsulated propranolol showed over 1.5-fold increases in the proliferation of human osteoblastic cells hFOB1.19 while differentiation of the cells was approximately doubled by plain and liposomal propranolol, indicating that the stimulatory effects of liposomal propranolol are similar with those of propranolol on human osteoblastic hFOB1.19 cells. The phosphatidylcholine liposomes-encapsulated propranolol prepared in this study potentially possesses anabolic effects in vivo and is also a promising anti-osteoporotic agent in future.
Keywords: Propranolol, DMPC, DSPC, liposome, human osteoblastic cells, drug delivery system
